【英文タイトル】PharmaPoint: Hepatitis B Virus (HBV) Therapeutics - Global Drug Forecast and Market Analysis to 2024

B型肝炎ウイルス(HBV)治療薬の世界市場予測・分析(~2024) (Code:GDHC117PIDR)


PharmaPoint: Hepatitis B Virus (HBV) Therapeutics – Global Drug Forecast and Market Analysis to 2024


Chronic hepatitis B virus (HBV) infection is a serious chronic liver disease caused by the failure of viral clearance following acute HBV infection. Despite the availability of effective prophylactic vaccines, the disease remains a serious global health concern, with estimated over 350 million people worldwide currently living with this condition. In addition, patients with chronic hepatitis B are at a high risk of developing life-threatening complications including liver cirrhosis and hepatocellular carcinoma (HCC). In 2010, an estimated 786,000 HBV-related deaths occurred worldwide.

Available treatment for chronic hepatitis B focuses on viral suppression, and include oral nucleos(t)ide analogues (NAs) and pegylated interferon (PEG-IFN). The two therapy classes have distinctive strengths and weaknesses. Nevertheless, most patients are using long-term NA treatment, and suffer from issues such as high accumulated treatment cost and low compliance.

For the purposes of this report, GlobalData defines the HBV infection therapeutics market to include sales of HBV-specific medication in patients 18 years and older in the eight major pharmaceutical markets (8MM; US, France, Germany, Italy, Spain, UK, Japan, and China). GlobalData expects the market to experience moderate growth that will be primarily driven by the uptake of therapies with novel mechanisms of action (MOAs).


Key Questions Answered

– How good is the management of chronic HBV infection with marketed therapies?
– Which drugs and players are important in the current management landscape?
– Which pipeline agents will enter the market during the forecast period (2014-2024)?
– Will the leading pipeline agents fulfil the unmet needs of current management landscape?
– What clinical and commercial factors are likely to influence HBV therapeutic uptake in the US, 5EU, Japan and China?

Key Findings

– GlobalData projects the HBV therapeutics market in the 8MM to grow from approximately $2.4 billion in 2014 to $3.0 billion in 2024, at a compound annual growth rate (CAGR) of 2.4%. This growth across the 8MM will primarily be driven by the launch of pipeline agents, especially those with novel MOAs, while steep generic erosion across the 8MM is expected to curtail market growth over the forecast period.
– While pipeline agents have the potential to address some of the unmet needs in the HBV treatment landscape, more clinical data are required to demonstrate their advantage over available therapies, according to interviewed KOLs. In addition, these agents are pioneers of novel therapies, which retain substantial room for future development.
– GlobalData anticipates that opportunities centered on the development of antivirals with novel MOAs, which can improve the efficacy of existing drugs, will exist for current and future players in the HBV therapeutic marketplace for the duration of the forecast period.


– Overview of chronic HBV infection, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options.
– Topline HBV therapeutics market revenue from 2014-2024. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
– Key topics covered include strategic competitor assessment, unmet needs, pipeline assessment, and market outlook for the HBV therapeutics market.
– Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
– Analysis of the current and future market competition in the global HBV therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to –
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
– Develop business strategies by understanding the trends shaping and driving the global HBV therapeutics market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HBV therapeutics market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
– Identify emerging players with potentially strong product portfolio





1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 16
1.2 List of Figures 20
2 Introduction 22
2.1 Catalyst 22
2.2 Related Reports 23
2.3 Upcoming Related Reports 24
3 Disease Overview 25
3.1 Overview 25
3.2 Etiology and Pathophysiology 26
3.2.1 Etiology 26
3.2.2 Pathophysiology 33
3.3 Symptoms 35
3.4 Prognosis 36
3.4.1 Phases of Chronic HBV Infection 37
3.4.2 Complications of Chronic Hepatitis B 41
3.5 Quality of Life 43
4 Epidemiology 45
4.1 Disease Background 45
4.2 Risk Factors and Comorbidities 46
4.3 Global Trends 47
4.4 Forecast Methodology 49
4.4.1 Sources Used 50
4.4.2 Sources Not Used 58
4.4.3 Forecast Assumptions and Methods 59
4.5 Epidemiological Forecast of Chronic Hepatitis B (2014-2024) 65
4.5.1 Diagnosed Prevalent Cases of Chronic Hepatitis B 65
4.5.2 Age-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B 67
4.5.3 Sex-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B 70
4.5.4 Age-Standardized Diagnosed Prevalence of Chronic Hepatitis B 72
4.5.5 Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by HBV DNA Level 74
4.5.6 Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by ALT Level 75
4.5.7 Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by HBeAg Status 76
4.5.8 Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by Cirrhosis Status 77
4.5.9 Diagnosed Prevalent Cases of Chronic Hepatitis B with Co-infection of HIV and Hepatitis C 79
4.6 Discussion 80
4.6.1 Epidemiological Forecast Insight 80
4.6.2 Limitations of the Analysis 80
4.6.3 Strengths of the Analysis 81
5 Disease Management 82
5.1 Diagnosis and Treatment Overview 82
5.1.1 Diagnosis 82
5.1.2 Treatment Guidelines and Leading Prescribed Drugs 83
5.1.3 Clinical Practice 85
5.2 US 90
5.2.1 Screening and Diagnosis 91
5.2.2 Clinical Practice 92
5.3 5EU 95
5.3.1 Screening and Diagnosis 96
5.3.2 Clinical Practice 97
5.4 Japan 101
5.4.1 Screening and Diagnosis 101
5.4.2 Clinical Practice 103
5.5 China 106
5.5.1 Screening and Diagnosis 107
5.5.2 Clinical Practice 109
6 Competitive Assessment 113
6.1 Overview 113
6.2 Product Profiles – Major Brands 117
6.2.1 Baraclude (entecavir) 117
6.2.2 Viread (tenofovir disoproxil fumarate) 122
6.2.3 Pegasys (peginterferon alfa-2a) 130
6.2.4 Hepsera (adefovir dipivoxil) 137
6.2.5 Tyzeka (telbivudine) 141
6.3 Other Therapeutics 147
6.3.1 Conventional and Pegylated Interferon alfa 147
6.3.2 Nucleos(t)ide Analogs 148
7 Unmet Needs and Opportunities 150
7.1 Overview 150
7.2 Improvements in Long-Term Clinical Outcomes 153
7.2.1 Unmet Need 153
7.2.2 Gap Analysis 156
7.2.3 Opportunity 160
7.3 Enhanced Public Awareness and Screening Initiatives to Boost Diagnosis Rates 163
7.3.1 Unmet Need 163
7.3.2 Gap Analysis 167
7.3.3 Opportunity 167
7.4 Increased Access to Treatment 168
7.4.1 Unmet Need 168
7.4.2 Gap Analysis 171
7.4.3 Opportunity 172
7.5 Drugs That Effectively Target and Suppress HBV cccDNA 173
7.5.1 Unmet Need 173
7.5.2 Gap Analysis 173
7.5.3 Opportunity 174
7.6 Safe and Efficacious Therapies for Difficult-to-Treat Patients 175
7.6.1 Unmet Need 175
7.6.2 Gap Analysis 176
7.6.3 Opportunity 177
7.7 Overcome Unique Barriers Posed by China’s Healthcare System 178
7.7.1 Unmet Need 178
7.7.2 Gap Analysis 179
7.7.3 Opportunity 179
8 Pipeline Assessment 181
8.1 Overview 181
8.2 Clinical Trial Mapping 182
8.2.1 Clinical Trials by Phase and Status, Therapy Class, and Location 182
8.3 Promising Drugs in Clinical Development 184
8.3.1 Tenofovir Alafenamide Fumarate 187
8.3.2 ARC-520 194
8.3.3 GS-9620 201
8.3.4 GS-4774 206
8.4 Other Drugs in Development 212
8.4.1 ABX-203 213
8.4.2 REP 2139-Ca 214
8.4.3 Besifovir 215
8.4.4 Hepabulin 215
8.4.5 Myrcludex-B 215
8.4.6 Agents in Early Stages of Development 216
9 Current and Future Players 219
9.1 Overview 219
9.2 Trends in Corporate Strategy 222
9.3 Company Profiles 225
9.3.1 Gilead 225
9.3.2 Bristol-Myers Squibb 227
9.3.3 Roche 229
9.3.4 Merck 230
9.3.5 GSK 233
9.3.6 Novartis 234
9.3.7 Arrowhead Research 235
9.3.8 GlobeImmune 236
10 Market Outlook 237
10.1 Global Markets 237
10.1.1 Forecast 237
10.1.2 Drivers and Barriers – Global Issues 243
10.2 US 245
10.2.1 Forecast 245
10.2.2 Key Events 249
10.2.3 Drivers and Barriers 250
10.3 5EU 2





■ タイトル:B型肝炎ウイルス(HBV)治療薬の世界市場予測・分析(~2024)
■ 英文:PharmaPoint: Hepatitis B Virus (HBV) Therapeutics - Global Drug Forecast and Market Analysis to 2024
■ 発行日:2016年1月1日
■ 調査会社:GlobalData
■ 商品コード:GDHC117PIDR
■ 調査対象地域:グローバル

B型肝炎ウイルス(HBV)治療薬の世界市場予測・分析(~2024) (PharmaPoint: Hepatitis B Virus (HBV) Therapeutics - Global Drug Forecast and Market Analysis to 2024 / GDHC117PIDR)

  • 応募者追跡システム(ATSソフトウェア)の世界市場
    About Applicant Tracking System ATS or Applicant Tracking System is an application that manages recruitment process of an organization. An ATS can be compared to CRM systems, but is specifically designed for recruitment tracking purposes. ATS collects resume in a database, and gives recruiters an online view of job seekers after scanning and indexing their resumes. Most organizations use some form …
  • Emerging Molecular and Immunohematology Blood Typing, Grouping and Infectious Disease NAT Screening Assays, and Companies Developing New Technologies and Products
    The report presents a comprehensive analysis of the clinical significance and market needs for major blood typing, grouping, and infectious disease screening assays, including NAT tests, as well as extensive listings of companies developing or marketing new blood banking technologies and products.Contains 197 pages and 6 tables
  • ネットワークアナライザの世界市場2016-2020
    About Network Analyzers Network analyzers are instruments that assist generation and analysis on multiple channels. These are usually costlier than spectrum analyzers and vector instruments and are typically used to measure scattering parameters (also known as S-parameters) and other characteristics of RF waves and high-frequency radiation. The primary use of network analyzers is to determine the …
  • 世界の税関審査/通関業者(カスタム・ブローカー)市場
    About Customs Audit Customs audit also termed as post clearance audit is the retrospective examination of goods, which are released after import and export under the policy of trade facilitation and customs control using tools such as risk management and standard customs procedures. The audit process is conducted through a thorough examination of company records, accounting systems, business syste …
  • スマート照明市場2014(Version1&2)
    NanoMarkets has been covering the smart lighting market for four years and has acquired an understanding of the key markets, technologies and companies in this rapidly expanding business. This year, NanoMarkets has decided to cover this interesting sector in two volumes. Volume I is devoted to an analysis of smart lighting markets and covering the basic drivers and economics of the smart lighting …
  • 圧力開放装置の世界市場の規模および予測:タイプ別(ローテク機器[フォームベース、ゲルベース、繊維充填、液体充填、エア充填マットレス]、ハイテク機器[ダイナミックエアーセラピー、キネティックベッド])、動向分析、2014-2025
    The global pressure relief devices market is expected to reach USD 4.1 billion by 2025, according to a new study by Grand View Research Inc. The rapidly growing number of elderly population worldwide and rising awareness about pressure ulcers through campaigns along with the increasing base of obese population are expected to drive the industry growth. The incidence of pressure ulcer development h …
  • 中国の移動補助・運搬機器市場見通し(~2021)
    China Mobility Aids and Transportation Equipment Market Outlook to 2021 Summary GlobalData’s new report, "China Mobility Aids and Transportation Equipment Market Outlook to 2021", provides key market data on the China Mobility Aids and Transportation Equipment market. The report provides value, in millions of US dollars, volume (in units) and average price data (in US dollars), within market segme …
  • 世界の農作物保護用化学薬品市場:除草剤、殺菌剤、殺虫剤
    The global crop protection chemicals market is segmented into all major regions and further, their key countries. In terms of regions, the report is segmented into North America, Europe, Asia-Pacific, Latin America, and Rest of the World (RoW). Asia-Pacific and North America are the top two consumers of crop protection chemicals, accounting together for nearly 50% of the total market share. Asia-P …
  • 対UAV(無人機)防衛システムの世界市場2016-2020
    About Counter UAV Defense System Counter UAV defense systems detect potential unmanned aerial vehicle (UAV) threats and find application in industries like military, homeland security, and airports. The system is a combination of radars, infrared cameras, and navigators that recognize drones and limit their risk capabilities. Jamming systems and technologies also play a pivotal role to ensure that …
  • 世界のゲーム市場:テレビ/コンソールゲーム、MMOゲーム、モバイルゲーム、ソーシャルゲーム、PCゲーム等
    About Games At the beginning, games were restricted to board games and associated video games. The introduction and popularity of PCs and electronic devices and the rise of the internet has led to the development and commercialization of gaming. Consumers are now yearning for interactive entertainment in the form of games. Games now have different genres and offer different user experiences across …
  • モーションセンサーの世界市場:ジャイロスコープ、磁力計、加速度計、コンボ
    About Consumer Motion Sensors Motion sensors are devices that detect any 3-dimensional motion. Micro-electro-mechanical-systems (MEMS), also called micromachines or micro systems technology, are miniaturized electro-mechanical systems. MEMS is a combination of microsensors, microactuators, microelectronics, and microstructures. The role of a microsensor is to convert mechanical signals into electr …
  • イタリアの気道装置・麻酔装置市場
    Italy Airway and Anesthesia Devices Market Outlook to 2021 Summary GlobalData’s new report, "Italy Airway and Anesthesia Devices Market Outlook to 2021", provides key market data on the Italy Airway and Anesthesia market. The report provides value, in millions of US dollars, volume (in units) and average price data (in US dollars), within market segments - Anesthesia Circuits, Anesthesia Masks, Ai …
  • 製造業におけるビックデータ市場調査(市場分析、事例研究、予測2014-2019)
    本レポートでは世界の主な産業におけるビックデータの市場分析、競合企業、ソリューション、事例分析、及び2014年~2019年までの予測が含まれている。 The manufacturing industry account for a significant share of GDP globally and represents a large ecosystem. The competition in manufacturing sector worldwide forces companies to get smarter through in-depth real time analysis of large datasets produced internally and externally for deep insight and quick decision making. B …
  • ウイルス性結膜炎治療薬の世界市場2016-2020
    About Viral Conjunctivitis Drugs Viral conjunctivitis, or pink eye, is a type of infectious conjunctivitis that is commonly caused by an adenovirus. Herpes simplex virus (HSV), picornavirus (enterovirus 70, Coxsackie A24), varicella-zoster virus, poxvirus (molluscum contagiosum and vaccinia), and human immunodeficiency virus (HIV) are some of the other viruses that are responsible for the infectio …
  • 自動車用テレマティクスの世界市場2016-2020
    About Automotive Telematics The automotive telematics system is a device that deals with communication (sending, receiving, and storing information) regarding the vehicle and other parameters. The telematics system collects information from different on-board sensors such as vehicle speed, braking system, advanced driver assistance systems (ADAS), airbags, transmission control system, and many oth …